Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma has now been rescheduled into the work programme. The appraisal is due to start early March 2022 and will be discussed at committee in early November 2022.
The new timelines are subject to the work programme capacity and we will continue to review our plans in collaboration with the company and update our stakeholders accordingly.